Table 2 Baseline risk factors significantly associated with cardiotoxicities following CAR T-cell therapy
From: Cardiovascular complications of cellular immunotherapies and associated risk factors
Study | Population | Sample size | CRS grade | CV risk factors | Biomarkers | Echocardiographic parameters |
|---|---|---|---|---|---|---|
Burstein, et al.24 | Pediatric B-ALL | 98 | Not Reported | None | Not Reported | Decreased LVEF |
Alvi, et al.25 | DLBCL & MM | 137 | Yes | None | Not Reported | None |
Lefebvre, et al.26 | NHL, B-ALL, & CLL | 145 | Yes | Prior arrhythmia | Not Reported | Increased LAVI, Increased MV E/e’ |
Shalabi, et al.27 | Pediatric B-ALL & NHL | 52 | Yes | None | Not Reported | Decreased GLS |
Ganatra, et al.28 | NHL | 187 | Yes | Older age, Prior HTN, Prior HLD, Prior CAD | None | None |
Brammer, et al.29 | NHL | 90 | Yes | None | None | None |
Wudhikarn, et al.31 | DLBCL | 60 | No | None | None | None |
Qi, et al. 202130 | B-ALL, NHL, & MM | 126 | Yes | None | Elevated creatinine | None |
Steiner, et al.35 | DLBCL | 165 | Yes | Older age | None | Diastolic dysfunction |
Lee, et al.32 | MM | 78 | Yes | None | None | None |
Lee, et al.33 | NHL | 90 | No | Older age | Elevated creatinine | Increased LAVI |
Mahmood, et al.34 | NHL & B-ALL | 202 | Yes | Prior HTN, Prior arrhythmia, Prior HF | Elevated troponin, Elevated BNP | Decreased LVEF |
Patel, et al.23 | NHL, CLL, & MM | 75 | No | None | None | Decreased GLS, Increased MV E/e’ |
Lefebvre, et al.40 (Prospective) | NHL & B-ALL | 44 | No | None | None | None |
Korell, et al.41 (Prospective) | NHL, B-ALL, & MM | 137 | No | None | None | None |
